![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » OVATION PHARMACEUTICALS ANNOUNCES FIRST NEW DRUG TREATMENT IN 20 YEARS FOR PREMATURE INFANTS WITH PATENT DUCTUS ARTERIOSUS
OVATION PHARMACEUTICALS ANNOUNCES FIRST NEW DRUG TREATMENT IN 20 YEARS FOR PREMATURE INFANTS WITH PATENT DUCTUS ARTERIOSUS
July 20, 2006
OVATION Pharmaceuticals announced its launch of the first new pharmaceutical product in 20 years to treat a potentially life-threatening congenital heart defect in premature infants. NeoProfen (ibuprofen lysine) Injection (10mg/mL) is indicated when usual medical management is ineffective to close a clinically significant patent ductus arteriosus (PDA), a condition in which a blood vessel (ductus arteriosus) in the heart fails to close after birth.
Business Wire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct